Evidence map›Paper›PMID 41413598›Full record

ArticleParasites & vectors2025

Efficacy of oral afoxolaner and a combination of afoxolaner, moxidectin, and pyrantel against Amblyomma maculatum in dogs.

Joseph Prullage, Jeffrey Shryock, Pascal Dumont, Liezl Whitehead, Stephen Yoon, Ricarda Süssenberger

Abstract readRandomized Controlled Trial, Veterinary
PubMed Full text at PMC Publisher
In one paragraph

Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Joseph PrullageBoehringer Ingelheim Animal Health, Missouri Research Center, 6498 Jade Rd, Fulton, MO, 65251, USA.
Jeffrey ShryockBoehringer Ingelheim Animal Health, Missouri Research Center, 6498 Jade Rd, Fulton, MO, 65251, USA.
Pascal DumontBoehringer Ingelheim Animal Health, Georgia Research Center, 1730 Olympic Dr, Athens, GA, 30601, USA.
Liezl WhiteheadClinvet International (Pty) Ltd, Uitzich Road, Bainsvlei, Bloemfontein, 9338, South Africa.
Stephen YoonBoehringer Ingelheim Animal Health, Georgia Research Center, 1730 Olympic Dr, Athens, GA, 30601, USA.
Ricarda SüssenbergerBoehringer Ingelheim Vetmedica GmbH, Binger Str. 173, 55216, Ingelheim Am Rhein, Germany. ricarda.suessenberger@boehringer-ingelheim.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAmblyomma maculatum is a tick with a broad host range that is undergoing an expansion of its range within the USA. When feeding the predilection sites on the host are the head and ears and due to the long mouthparts, it can cause significant lesions that can lead to infection. It has also been implicated as a vector of Hepatozoon americanum, the causative agent of canine hepatozoonosis and a spotted fever group Rickettsia, Rickettsia parkeri.

methodsTwo randomized, blinded, negative controlled studies were conducted to determine whether treatment with afoxolaner (NexGard

resultsNexGard

conclusionsThe results of these studies demonstrate that NexGard

Indexed as

AcaricidesAmblyommaDog DiseasesIsoxazolesMacrolidesNaphthalenesPyrantelTick InfestationsAdministration, OralAnimalsDogsDrug Therapy, CombinationFemaleMaleTreatment OutcomeAcaricidesafoxolanerIsoxazolesMacrolidesmoxidectinNaphthalenesPyrantelAfoxolanerAmblyomma maculatumCanineControlTreatment

Identifiers

PMID41413598
PMCPMC12828931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.